- Home
- FRA vs AUTL Comparison
FRA vs AUTL Comparison
Compare FRA & AUTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | FRA | AUTL |
|---|---|---|
| Founded | 2003 | 2014 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Investment Bankers/Brokers/Service | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 415.1M | 407.2M |
| IPO Year | N/A | 2025 |
Fundamental Metrics
Financial Performance| Metric | FRA | AUTL |
|---|---|---|
| Price | $11.06 | $1.61 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $8.50 |
| AVG Volume (30 Days) | 115.5K | ★ 1.4M |
| Earning Date | 01-01-0001 | 05-14-2026 |
| Dividend Yield | ★ 11.06% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $10,120,000.00 |
| Revenue This Year | N/A | $80.32 |
| Revenue Next Year | N/A | $53.96 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 496.00 |
| 52 Week Low | $10.50 | $1.18 |
| 52 Week High | $13.41 | $2.70 |
Technical Indicators
Market Signals| Indicator | FRA | AUTL |
|---|---|---|
| Relative Strength Index (RSI) | 48.12 | 54.00 |
| Support Level | $10.94 | $1.25 |
| Resistance Level | $11.24 | $1.73 |
| Average True Range (ATR) | 0.12 | 0.10 |
| MACD | -0.00 | 0.01 |
| Stochastic Oscillator | 37.14 | 59.72 |
Price Performance
Historical ComparisonAbout FRA Blackrock Floating Rate Income Strategies Fund Inc
Blackrock Floating Rate Inc Stra Fd Inc is a United States-based diversified closed-ended management investment company. The Fund's investment objective is to provide shareholders with high current income and preservation of capital with investment in a diversified, leveraged portfolio consisting of floating-rate debt securities and instruments.
About AUTL Autolus Therapeutics plc
Autolus Therapeutics PLC is a biopharmaceutical company developing next-generation programmed T-cell therapies for the treatment of cancer. The company's clinical-stage pipeline comprises Obe-cel (obecabtagene autoleucel), AUTO1/22, AUTO3, AUTO5, AUTO6, AUTO7 & AUTO8. Company's T cell programming technologies tailors therapies to address the specific disease targeting and introduce new programming modules into a patient's T cells to give those T cells improved properties to recognize target cells and overcome fundamental disease defense mechanisms.